
News|Articles|June 10, 2026
How the Chai Discovery–Eli Lilly Collaboration Could Advance the Future of AI-Driven Biologics Development
Author(s)Danielle Valletti, Assistant Editor
Fact checked by: Ron Panarotti
Chai Discovery’s collaboration with Eli Lilly highlights the growing role of AI in biologics discovery, leveraging generative AI models to accelerate design and optimization of novel therapeutic proteins and antibodies.
Advertisement
Advertisement
Artificial intelligence (AI) continues to reshape pharmaceutical research, particularly in the discovery and optimization of biologic therapies. In January 2026, Chai Discovery announced a collaboration with Eli Lilly and Company to accelerate biologics discovery by deploying advanced AI models to design novel therapeutic proteins and antibodies.1
Related to this article

With a mifepristone safety review due by March and Senate control shifting in January, the FDA faces an extended stretch without a permanent leader.

Extended INDIGO and FIREFLY-1 results presented at SNO 2026 put seizure burden during vorasidenib therapy and time off tovorafenib in pediatric low-grade glioma into focus.

Pharmacists can help patients start buprenorphine for opioid use disorder by confirming when to take the first dose, whether another opioid continues during initiation, and who will manage symptoms and follow-up.

In older veterans, mRNA-1283 was associated with lower risks of medically attended COVID-19 and hospitalization than BNT162b2.

Pharmacists can use medication therapy management to screen for diabetes, educate patients about medication adherence and lifestyle modifications, and support early action.

In a phase 3 trial of children aged 6 to younger than 12 years, once-weekly semaglutide reduced BMI 16.2 percentage points more than placebo at 68 weeks.
Advertisement
Advertisement


